O4‐01‐04: Beneficial Effects of Angiotensin II Receptor Blockers on Metabolic Disorder‐induced Cognitive Impairment

Jun Iwanami,Masaki Mogi,Kana Tsukuda,Li-Juan Min,Akiko Sakata,Fei Jing,Masaru Iwai,Masatsugu Horiuchi
DOI: https://doi.org/10.1016/j.jalz.2010.05.468
2010-01-01
Abstract:Recent basic and clinical evidence indicate that renin-angiotensin system (RAS) is involved in metabolic syndrome and diabetes mellitus (DM) as well as hypertension. Metabolic syndrome and DM have been reported to be crucial risk factor for cognitive impairment including Alzheimer's disease. Increasing number of patients with metabolic syndrome and DM suggests that such cognitive decline will become a major worldwide clinical problem in the future. Here, we investigated the roles of angiotensin II and effect of angiotensin II receptor blockers (ARB) in cognitive function. Various mice models were employed. C57BL/6J mice with normal diet (ND), C57BL/6J mice with high-salt and high-cholesterol diet (HCD) as metabolic syndrome-like state, KK-Ay mice as type 2DM, and Tsukuba-Hypertensive-Mice (THM) as human angiotensin II overproducing model were employed in this study. These mice were subjected to passive avoidance task every week with or without ARB. 1) HCD mice showed a significant reduction of avoidance rate compared with ND mice. This impairment was prevented by treatment with non-hypotensive dose of ARB, olmesartan, partly due to a decrease in superoxide anion production. 2) Learning ability evaluated by an increase in avoidance rate was less in KK-Ay mice and significant cognitive impairment was observed after 14 weeks-old. Administration of non-hypotensive dose of candesartan from 8 weeks-old markedly improved learning ability and its administration from 14 weeks-old prevented further cognitive decline. Candesartan significantly decreased serum glucose and insulin levels and increase glucose-uptake in the brain. 3) THM exhibited a failure to increase the avoidance rate compared with control mice. Treatment with ARB, olmesartan, which decreases blood pressure to the same level as C57BL/6J, improved the avoidance rate. However, treatment with hydralazine for the THM did not show an improvement of avoidance rate although hydralazine decreased blood pressure to the same level of olmesartan treatment. Olmesartan attenuated superoxide anion production in the brain and improved the reduction of cerebral blood flow observed in THM. These results suggest that brain RAS plays an important role in cognitive function. Regulation of RAS using ARB is expected to prevent cognitive decline associated with metabolic syndrome, DM and hypertension.
What problem does this paper attempt to address?